trending Market Intelligence /marketintelligence/en/news-insights/trending/NPcmagtNCVorYZNL6Z4ddg2 content esgSubNav
In This List

CymaBay prices common stock offering

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


CymaBay prices common stock offering

CymaBay Therapeutics Inc. priced its underwritten public offering of 5,181,348 common shares at $1.93 per share, before underwriting discounts and commissions.

The company granted underwriters an overallotment option to buy up to an additional 777,202 shares.

CymaBay is expected to use the net proceeds to fund ongoing development of seladelpar, a drug for biliary cholangitis — a liver disease and for working capital and general corporate purposes.

The offering is expected to close Feb. 7, subject to customary closing conditions.

JonesTrading Institutional Services LLC is the sole book-running manager and LifeSci Capital LLC is the lead manager for the offering.